ECA
EW icon

Elevated Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Elevated Capital Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$814 Hold
9
– – ﹤0.01% 759
2026
Q1 		$721 Hold
9
– – ﹤0.01% 763
2025
Q4 		$767 Buy
+9
New +$739 ﹤0.01% 733

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Elevated Capital Advisors's EW Position: Q2 2026 in Review

Elevated Capital Advisors held its Edwards Lifesciences (EW) position steady in Q2 2026 at 9 shares worth $814. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Elevated Capital Advisors first reported a position in EW in Q4 2025 and has held it in 3 quarters since. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Elevated Capital Advisors held 9 shares of Edwards Lifesciences worth $814 as of Q2 2026.
  • Elevated Capital Advisors left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Elevated Capital Advisors's portfolio in Q2 2026, its #759 holding.
  • Elevated Capital Advisors first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 3 quarters since.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.